GCM
BEAM icon

Goldstream Capital Management’s Beam Therapeutics BEAM Stock Holding History

Goldstream Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,096
Closed -$1.44M – 21
2021
Q4 		$1.44M Buy
+18,096
New +$1.55M 0.35% 31

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldstream Capital Management's BEAM Position: Q1 2022 in Review

Goldstream Capital Management sold out of Beam Therapeutics (BEAM) in Q1 2022, closing a stake of 18,096 shares — an estimated $1.44M sold.

Goldstream Capital Management first reported a position in BEAM in Q4 2021 and held it in 1 quarter. The position peaked at $1.44M in Q4 2021. 240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

  • Goldstream Capital Management reported no remaining Beam Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 18,096 Beam Therapeutics shares in Q1 2022, an estimated $1.44M.
  • Goldstream Capital Management first reported a position in Beam Therapeutics in Q4 2021 and held it in 1 quarter.
  • Goldstream Capital Management's Beam Therapeutics position peaked at $1.44M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on Goldstream Capital Management's 13F filing for Q1 2022, filed 13 May 2022.